Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $156.50 Average PT from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $156.50.

ABVX has been the topic of a number of recent analyst reports. Leerink Partners increased their price target on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Guggenheim restated a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Wolfe Research set a $136.00 target price on Abivax in a research note on Wednesday, June 3rd. Wedbush increased their target price on Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th. Finally, BTIG Research lifted their price target on shares of Abivax from $150.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th.

Hedge Funds Weigh In On Abivax

Hedge funds have recently made changes to their positions in the company. TCG Crossover Management LLC boosted its stake in shares of Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after acquiring an additional 1,055,000 shares during the last quarter. UBS Group AG raised its stake in Abivax by 2,561.0% in the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after purchasing an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. raised its stake in Abivax by 0.4% in the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock valued at $439,714,000 after purchasing an additional 14,000 shares during the last quarter. Morgan Stanley lifted its holdings in Abivax by 114.3% in the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock valued at $425,062,000 after purchasing an additional 1,681,277 shares in the last quarter. Finally, Vestal Point Capital LP lifted its holdings in Abivax by 90.0% in the 4th quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after purchasing an additional 900,000 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Performance

Shares of Abivax stock opened at $130.93 on Friday. The firm has a 50-day simple moving average of $118.46 and a two-hundred day simple moving average of $118.69. Abivax has a fifty-two week low of $67.15 and a fifty-two week high of $148.83. The company has a market cap of $11.42 billion, a P/E ratio of -25.13 and a beta of 1.03.

Abivax (NASDAQ:ABVX) last posted its earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. Equities research analysts forecast that Abivax will post -3.22 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.